PASSION . BIO
Where science grows
Clinical development is where therapeutic potential is either realized or abandoned, often for reasons unrelated to scientific merit. When large pharma and biotech companies shift priorities, promising programs get shelved regardless of their clinical merit. PassionBio Capital was formed around the belief that the strongest of those programs deserve the focus and capital to carry that work through.
Underutilized
assets.
High-need
therapeutics.
PassionBio Capital targets
underutilized biopharma asset
where medical need is high and existing therapies fall short, in particular poor prognosis cancers, obesity in transitional markets, liver disease, and ME/CFS.
Each area was selected against two questions: does a clinically meaningful improvement over the future standard of care deliver real impact for patients, and can our team credibly contribute to achieving it.
Regulated
Therapeutic Focus
Obesity
Cancer
Liver
ME/CFS
Access to fund documentation is provided to eligible investors in accordance with applicable regulatory requirements.
Legal name
PBC I EuVECA GmbH & Co. KG
Register
FN 672223p
Adress
Wasagasse 11/9, 1090 Vienna
EUID
ATBRA.672223-000
How We
Work
The fund's sourcing originates from direct relationships with the scientists, clinicians, and development teams who built the programs we evaluate, often before they become broadly visible. We have worked from the inside on the same class of assets we now invest in. We know their development history, their failure modes, and where the residual value sits.
We target programs at clinical and late preclinical inflection points where a defined next milestone is the primary value driver and where our operational involvement in clinical plan design materially increases the probability of reaching it.
Portfolio construction is concentrated by design. Each position receives the level of operational attention that justifies the conviction behind it. Exit timelines are anchored to trade sale readiness.
Once a program enters formal evaluation, assessment covers scientific rationale, mechanism of action, regulatory pathway, clinical development options, manufacturing feasibility, and commercial positioning. For programs at the clinical stage, this includes independent review of existing data packages and a structured assessment of what a redesigned development plan would require in terms of time, capital, and risk.
Programs that pass evaluation are presented to the Investment Committee with a full IC Memo covering investment thesis, deal structure, milestone framework, and exit pathway. The Committee includes members with direct drug development experience across oncology, metabolic disease, and rare conditions. Formal investment decisions are executed by the General Partner, Infra.One AT Management GmbH, in accordance with the LPA and applicable regulatory requirements.
Post-investment, PassionBio remains the operational counterpart for each portfolio program. Clinical protocol design, CRO selection, regulatory strategy, and milestone tracking are managed through the same team that sourced and evaluated the asset. The fund does not hand off programs after closing a transaction.
Therapeutic Focus
Achieve clinically meaningful survival extension for patients with cancers of extremely poor prognosis, setting new standards beyond current therapies.
Cancers such as pancreatic, glioblastoma, or advanced lung and biliary cancers remain largely untreatable. Most patients die within months, and existing therapies offer limited efficacy while severely impacting quality of life. Innovation has stagnated, and progress is incremental at best. Developing therapies that extend overall survival by a clinically meaningful factor versus the future standard of care delivers tangible hope where medicine has so far failed.
Enable effective and affordable obesity treatment in transitional countries, achieving ≥20% weight reduction within one year while maintaining muscle mass and long-term health.
Populations in transitional countries face a rapidly growing obesity and cardiovascular disease pandemic, driven by rising incomes and carb-heavy diets. Unlike developed markets, these healthcare systems lack the resources for current GLP-1-based therapies. Providing scalable, accessible solutions addresses a critical public health challenge and unlocks a multi-billion market opportunity.
Prevent liver failure, cancer progression, and the need for transplantation, reducing individual suffering and systemic healthcare costs.
With rising obesity and type 2 diabetes, a wave of MASH is emerging, often overlapping with chronic viral hepatitis. Despite viral control, patients face silent fibrosis progression and increasing liver cancer risk. Healthcare systems face unsustainable treatment and transplant costs. Addressing this "time-bomb" represents one of the largest untapped markets in biopharma.
Enable restoration of daily functioning through therapies that deliver measurable and lasting symptom relief within months rather than years.
Post-viral fatigue syndromes such as ME/CFS and post-COVID syndrome cause profound exhaustion, cognitive impairment, and loss of independence, often persisting long after the initial infection. Despite the high disease burden and societal cost, treatment options remain absent. Leveraging existing compounds from mitochondrial, neuroinflammatory, and metabolic programs enables a rapid, translational path toward therapies that address underlying dysregulation of energy metabolism and neuroimmune balance.